Xceed Molecular, Moffitt Cancer Center, University of Manchester, Tepnel Life Sciences, GE Healthcare, University of Pittsburgh Medical Center, Omnyx, Procarta Biosystems, Iatrica, Research Corporation Technologies, SonoSite, University of Rochester, Los | GenomeWeb
Xceed Molecular Licenses Moffitt Gene Signature for Colon Cancer Dx Research
Xceed Molecular has licensed the rights to use a gene signature for colon cancer from the Moffitt Cancer Center, the company said this week.
The Wellesley, Mass.-based firm has purchased the worldwide, exclusive rights to use the gene signature to develop a molecular test that can predict patient prognosis for the disease, which Xceed said is diagnosed in over 100,000 Americans each year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.